MorphicLogo.jpg
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
10 août 2020 07h00 HE | Morphic Therapeutic
Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...
MorphicLogo.jpg
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
18 juin 2020 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic to Present at the Jefferies Virtual Healthcare Conference
27 mai 2020 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
06 mai 2020 16h05 HE | Morphic Therapeutic
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as CFO and COO ...
MorphicLogo.jpg
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
29 avr. 2020 16h15 HE | Morphic Therapeutic
WALTHAM, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
07 avr. 2020 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
28 févr. 2020 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
27 févr. 2020 16h05 HE | Morphic Therapeutic
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel Disease
14 févr. 2020 11h29 HE | Morphic Therapeutic
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro and in vivo models ...
MorphicLogo.jpg
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
08 janv. 2020 12h00 HE | Morphic Therapeutic
WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...